GlassScriptPhysician profile
Kristine E Gable
NPI 1851592604
$471.94
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.48 · 2023: $413 · 2024: $46.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.24 | 2023 | |
| Sk Life Science, INC. | $49.50 | 2023 | |
| Lundbeck LLC | $47.31 | 2023-2024 | Rexulti, Vyepti |
| Ucb, INC. | $45.86 | 2023 | Briviact |
| Abbvie INC. | $40.98 | 2023 | |
| Csl Behring | $35.00 | 2023 | Hizentra |
| Lilly USA, LLC | $32.96 | 2023 | Emgality |
| Argenx US, INC. | $27.35 | 2023 | Vyvgart |
| Teva Pharmaceuticals USA, INC. | $22.16 | 2024 | Ajovy |
| Horizon Therapeutics Plc | $21.43 | 2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $20.36 | 2023 | Rytary |
| Genentech USA, INC. | $18.49 | 2023 | Ocrevus |
| Astrazeneca Pharmaceuticals LP | $16.97 | 2023 | Wainua |
| Novartis Pharmaceuticals Corporation | $15.03 | 2023 | |
| Banner Life Sciences, LLC | $13.82 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Gable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.